DexCom (NASDAQ: DXCM) reported Q4 EPS of $0.91, $0.01 worse than the analyst estimate of $0.92. Revenue for the quarter came in at $568.9 million versus the consensus estimate of $554.7 million.

GUIDANCE:

DexCom sees FY2021 revenue of $2.21-2.31 billion.

• Non-GAAP Gross profit margin of approximately 65%
• Non-GAAP Operating margin of approximately 13%
• Adjusted EBITDA margin of approximately 23%

For earnings history and earnings-related data on DexCom (DXCM) click here.